Open AccessS132: TOLERABILITY AND EFFICACY OF THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53‐MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
Author(s) -
Daver N. G.,
Vyas P.,
Kambhampati S.,
Al Malki M. M.,
Larson R.,
Asch A.,
Mannis G.,
ChaiHo W.,
Tanaka T.,
Bradley T.,
Jeyakumar D.,
Wang E.,
Xing G.,
Chao M.,
Ramsingh G.,
Renard C.,
Lal I.,
Zeidner J.,
Sallman D.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843420.50062.9b
Subject(s) - medicine , tolerability , febrile neutropenia , neutropenia , azacitidine , decitabine , adverse effect , myeloid leukemia , gastroenterology , nausea , chemotherapy , biochemistry , gene expression , chemistry , dna methylation , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom